Oncolytic virotherapy of ovarian cancer

Exploring Myxoma virus oncolytic virotherapy in combination with carboplatin for the treatment of epithelial ovarian cancer

Targeting Cancer-Initiating Cells Growth by Decreasing Immunosuppression Virotherapy Inhibits Ovarian Cancer CXCL12/CXCR4 Blockade by Oncolytic

Oncolytic virotherapy for ovarian cancer

In the past two decades, more than 20 viruses with selective tropism for tumor cells have been developed as oncolytic viruses (OVs) for treatments of a variety of malignancies. Of these viruses, eleven have been tested in human ovarian cancer models in preclinical studies. So far, nine phase I or II clinical trials have been conducted or initiated using four different types of OVs in patients w...

Cancer virotherapy: Targeting cancer cells by microRNA mechanism for selective replication of oncolytic viruses in these cells

Cancer, as one of the most serious public health problems, is the second-leading cause of death in the world after cardiovascular disease. The number of patients and the resulting mortality are increasing worldwide; therefore, early diagnosis, prevention, and effective treatment of cancer are very important. Current treatments such as chemotherapy and radiation therapy are often non-selective a...

VSV based virotherapy in ovarian cancer: the past, the present and …future?

The standard approach to treating patients with advanced epithelial ovarian cancer (EOC) after primary debulking surgery remains taxane and platinum-based chemotherapy. Despite treatment with this strategy, the vast majority of patients relapse and develop drug-resistant metastatic disease that may be driven by cancer stem cells (CSCs) or cancer initiating cells (CICs). Oncolytic viruses circum...